Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Marta Cremonesi

Showing results (1-10 of 103) with videos related to

Pageof 11
Sort By:
Cancer Biotherapy & Radiopharmaceuticals|January 6, 2011
Something more than estimating renal dosimetryLisa Bodei, Marta Cremonesi, Giovanni Paganelli
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|September 3, 2017
Individualized Dosimetry for Theranostics: Necessary, Nice to Have, or Counterproductive?Uta Eberlein, Marta Cremonesi, Michael Lassmann
The Quarterly Journal of Nuclear Medicine and Molecular Imaging : Official Publication of the Italian Association of Nuclear Medicine (AIMN) [And] the International Association of Radiopharmacology (IAR), [And] Section of the Society Of|December 9, 2021
Dosimetry of nuclear medicine therapies: current controversies and impact on treatment optimizationFrancesco Cicone, Silvano Gnesin, Marta Cremonesi
PET Clinics|July 18, 2014
Yttrium-based therapy for neuroendocrine tumorsLisa Bodei, Marta Cremonesi, Giovanni Paganelli
Seminars in Nuclear Medicine|April 20, 2002
Receptor-mediated radiotherapy with Y-DOTA-DPhe-Tyr-octreotide: the experience of the European Institute of Oncology GroupMarco Chinol, Lisa Bodei, Marta Cremonesi, et al.
European Journal of Nuclear Medicine and Molecular Imaging|September 26, 2002
Facts and myths about radiopeptide therapy: Scylla, Charybdis and SibylLisa Bodei, Marco Chinol, Marta Cremonesi, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 28, 2009
Hematologic toxicity and double autografting of stem cells after myeloablative activities of yttrium-90-ibritumomab tiuxetanAnna Vanazzi, Marta Cremonesi, Giovanni Paganelli, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|September 7, 2006
Dosimetry in Peptide radionuclide receptor therapy: a reviewMarta Cremonesi, Mahila Ferrari, Lisa Bodei, et al.
European Journal of Nuclear Medicine and Molecular Imaging|May 20, 2004
Receptor radionuclide therapy with 90Y-[DOTA]0-Tyr3-octreotide (90Y-DOTATOC) in neuroendocrine tumoursLisa Bodei, Marta Cremonesi, Chiara Grana, et al.
Journal of Biomedical Optics|May 10, 2016
Cerenkov and radioluminescence imaging of brain tumor specimens during neurosurgeryAntonello Enrico Spinelli, Marco P Schiariti, Chiara M Grana, et al.
Pageof 11

Showing results (1-10 of 103) with videos related to

Sort By:
Pageof 11
Cancer Biotherapy & Radiopharmaceuticals|January 6, 2011
Something more than estimating renal dosimetryLisa Bodei, Marta Cremonesi, Giovanni Paganelli
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|September 3, 2017
Individualized Dosimetry for Theranostics: Necessary, Nice to Have, or Counterproductive?Uta Eberlein, Marta Cremonesi, Michael Lassmann
The Quarterly Journal of Nuclear Medicine and Molecular Imaging : Official Publication of the Italian Association of Nuclear Medicine (AIMN) [And] the International Association of Radiopharmacology (IAR), [And] Section of the Society Of|December 9, 2021
Dosimetry of nuclear medicine therapies: current controversies and impact on treatment optimizationFrancesco Cicone, Silvano Gnesin, Marta Cremonesi
PET Clinics|July 18, 2014
Yttrium-based therapy for neuroendocrine tumorsLisa Bodei, Marta Cremonesi, Giovanni Paganelli
Seminars in Nuclear Medicine|April 20, 2002
Receptor-mediated radiotherapy with Y-DOTA-DPhe-Tyr-octreotide: the experience of the European Institute of Oncology GroupMarco Chinol, Lisa Bodei, Marta Cremonesi, et al.
European Journal of Nuclear Medicine and Molecular Imaging|September 26, 2002
Facts and myths about radiopeptide therapy: Scylla, Charybdis and SibylLisa Bodei, Marco Chinol, Marta Cremonesi, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 28, 2009
Hematologic toxicity and double autografting of stem cells after myeloablative activities of yttrium-90-ibritumomab tiuxetanAnna Vanazzi, Marta Cremonesi, Giovanni Paganelli, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|September 7, 2006
Dosimetry in Peptide radionuclide receptor therapy: a reviewMarta Cremonesi, Mahila Ferrari, Lisa Bodei, et al.
European Journal of Nuclear Medicine and Molecular Imaging|May 20, 2004
Receptor radionuclide therapy with 90Y-[DOTA]0-Tyr3-octreotide (90Y-DOTATOC) in neuroendocrine tumoursLisa Bodei, Marta Cremonesi, Chiara Grana, et al.
Journal of Biomedical Optics|May 10, 2016
Cerenkov and radioluminescence imaging of brain tumor specimens during neurosurgeryAntonello Enrico Spinelli, Marco P Schiariti, Chiara M Grana, et al.
Pageof 11